Abstract
Nivolumab and Nintedanib (in combination with docetaxel) are both established 2nd-line treatments in non-squamous NSCLC. The NintNivo trial was conducted to explore the therapeutic potential of the combination of immune checkpoint inhibition (Nivolumab) and anti-angiogenesis (Nintedanib) in advanced treatment lines of NSCLC with adenocarcinoma histology. We hypothesized that the combination of both substances increases efficacy in the 2nd/3rd-line setting and may even restore tumor response with IO refractory patients progressing after IO + platinum-based front-line treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
